SAN DIEGO, May 4, 2005 /PRNewswire-FirstCall via COMTEX/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it will report its unauditedfinancial results for the first quarter ended March 31, 2005 on Wednesday,May 11, 2005, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, VicePresident and Chief Financial Officer, will host a conference call and webcaston Wednesday, May 11, 2005 at 4:30 p.m. Eastern Time to discuss ACADIA'sfinancial results and provide an update on the company's business.
The conference call may be accessed by dialing 866-761-0749 forparticipants in the U.S. or Canada and 617-614-2707 for international callers(reference passcode 64396418). A telephone replay of the conference call maybe accessed through May 25, 2005 by dialing 888-286-8010 for callers in theU.S. or Canada and 617-801-6888 for international callers (reference passcode89884568). The conference call also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archived thereuntil May 25, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of novel treatmentsfor central nervous system disorders. ACADIA currently has four drug programsin clinical development as well as a portfolio of preclinical and discoveryassets directed at large unmet medical needs, including schizophrenia,Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietarydrug discovery platform, ACADIA has discovered all of the drug candidates inits product pipeline. ACADIA's corporate headquarters is located in SanDiego, California and it maintains research and development operations in bothSan Diego and Scandinavia.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
+1 858-558-2871